How the protein CARMIL1 affects lung blood-vessel leak
CARMIL1 and Endothelial Barrier Function Regulation
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11180389
Researchers are looking at whether differences in the protein CARMIL1 help protect people with ARDS from lung blood-vessel leak and severe fluid buildup.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11180389 on ClinicalTrials.gov |
What this research studies
This project focuses on a gene called LRRC16A that makes the protein CARMIL1, which helps shape the cell skeleton. Researchers will test how CARMIL1 controls actin structures and membrane protrusions in cells that line lung blood vessels to see how those changes affect leakiness. They will manipulate CARMIL1 levels in lab-grown endothelial cells and link those findings to human genetic variants already tied to better ARDS outcomes. The work aims to connect patient genetics to a clear cell-level mechanism that could guide future therapies to reduce lung flooding.
Who could benefit from this research
Good fit: Adults who have had ARDS, are at high risk for ARDS, or are willing to provide blood or medical records for genetic study would be most relevant for this research.
Not a fit: People without lung blood-vessel leak or health issues unrelated to ARDS are unlikely to get direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could point to new ways to strengthen lung blood-vessel barriers and reduce deadly fluid buildup in ARDS.
How similar studies have performed: Previous studies have linked LRRC16A variants to ARDS outcomes, but the specific role of CARMIL1 in endothelial barrier function is largely new and not yet proven.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BELVITCH, PATRICK — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: BELVITCH, PATRICK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Lung Injury, Acute Pulmonary Injury, Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome